Ke Wang
- Infectious Diseases top 2%
-
- Lung Cancer Treatments and Mutations 20
- Chronic Obstructive Pulmonary Disease (COPD) Research 18
- Respiratory Support and Mechanisms 17
- Lung Cancer Diagnosis and Treatment 10
- Neonatal Respiratory Health Research 9
- Cancer Research top 5%
- MicroRNA in disease regulation 11
- Cancer, Lipids, and Metabolism 9
- Immunology top 5%
-
- Asthma and respiratory diseases 14
- Co-authors
- Shouming QinQiang FuQiuli LiangXuejun QinHuan‐Zhong ShiKui LiuLei ChenJin Shang
- Journals
- PLoS ONE (8 papers)Scientific Reports (8 papers)International Immunopharmacology (6 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Ke Wang
271 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 182
- Infectious Diseases 905
- Pulmonary and Respiratory Medicine 1.4k
- Cancer Research 550
- Critical Care and Intensive Care Medicine 183
- Immunology 701
Countries citing papers authored by Ke Wang
This map shows the geographic impact of Ke Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Wang more than expected).
Fields of papers citing papers by Ke Wang
This network shows the impact of papers produced by Ke Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Wang. The network helps show where Ke Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ke Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 9 | |
| 7 | 2023 | 10 | |
| 8 | 2022 | 4 | |
| 9 | 2022 | 6 | |
| 10 | 2022 | 4 | |
| 11 | 2021 | 6 | |
| 12 | 2020 | 6 | |
| 13 | 2020 | 1 | |
| 14 | 2019 | 7 | |
| 15 | 2018 | 12 | |
| 16 | 2018 | 2 | |
| 17 | 2012 | 264 | |
| 18 | 2012 | 110 | |
| 19 | Diagnostic significance of examining the plasma levels of D-dimer and FDP in disseminated intravascular coaguIation(DIC) | 2004 | 0 |
| 20 | A Randomized Controlled Clinical Study of Terbinafine Powder Versus Miconazole for the Treatment of Tinea mamun/Pedis and Tinea Corporis/Cruris | 2000 | 1 |
About Ke Wang
Ke Wang is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 289 papers that have together received 5.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (20 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers), Respiratory Support and Mechanisms (17 papers), Asthma and respiratory diseases (14 papers), MicroRNA in disease regulation (11 papers), Lung Cancer Diagnosis and Treatment (10 papers), Neonatal Respiratory Health Research (9 papers) and Cancer, Lipids, and Metabolism (9 papers). The work is most often cited by research in Infectious Diseases (905 citations), Pulmonary and Respiratory Medicine (1.4k citations) and Cancer Research (550 citations). Ke Wang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Shouming Qin, Qiang Fu, Qiuli Liang, Xuejun Qin, Huan‐Zhong Shi, Kui Liu, Lei Chen, Jin Shang, Yan Deng and Shuang Wei. Their work appears in journals such as PLoS ONE, Scientific Reports, International Immunopharmacology, Medicine and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.